FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029206266> ?p ?o ?g. }

• W2029206266 abstract "Melanoma cells are notoriously resistant to conventional therapeutics (some of which trigger the intrinsic mitochondrial‐based apoptotic pathway), whilst some melanoma cells are also resistant to extrinsic death ligand‐mediated apoptosis. Emerging studies focused on metabolomics of cancer cells revealed that metabolic alterations in tumors could be exploited as novel targets for cancer therapy. Many tumor cells not only display a high rate of glucose uptake and glycolysis, but also exhibit increased glutamine consumption. In this study, apoptotic susceptibility to tumor necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL/APO2L) was investigated in four human melanoma cell lines in the presence of a metabolic inhibitor of glucose (2‐deoxyglucose, 2DG, 10 mM) or glutamine (aminooxyacetate; AOA; 1mM, inhibitor of glutamate dependent transaminase). 2DG or AOA alone did not trigger significant apoptosis measured by Annexin V‐PI staining and FACS analysis in these melanoma cell lines within a period of 24 hrs. However, the combined treatment with either 2DG plus TRAIL (100ng/ml), or AOA plus TRAIL, significantly induced apoptosis in 3 of 4 melanoma cell lines, compared to a single treatment protocol. Furthermore, the co‐treatment selectively enhanced TRAIL mediated cytotoxicity only in melanoma cells, but not in normal human melanocytes or skin derived dermal fibroblasts. To more firmly establish the vital links between inhibition of glucose or glutamine metabolism and TRAIL efficacy, melanoma cells were also cultured with medium depleted of either glucose or glutamine for 1 day followed by adding TRAIL for another 24 hrs. Withdrawal of either glucose or glutamine by itself induced low level of spontaneous apoptosis in both melanoma cell lines tested. Similar to the treatment with 2DG or AOA, withdrawal of glucose or glutamine also sensitized both melanoma cell lines to TRAIL mediated apoptosis. The apoptosis induced by co‐treatment with 2DG or AOA plus TRAIL was markedly blocked by a pan caspase inhibitor (Z‐VAD), implicating a caspase‐dependency. Western blotting analysis confirmed cotreatments effectively induced caspases 3 cleavage and Bid degradation in melanoma cells. Additionally 2DG or AOA plus TRAIL also resulted in loss of mitochondrial membrane potential (reduced Rhodamine123 uptake). Furthermore, both 2DG and AOA changed the balance between anti‐ and pro‐ apoptotic proteins of Bcl‐2 family members. AOA was a stronger inducer compared to 2DG in enhancing BH3‐only protein Noxa levels. 2DG was more effective in reducing Bcl‐XL levels, while AOA more strongly inhibited Mcl‐1 expression. Taken together, the findings of this study described a novel strategy to overcome the apoptotic resistance of melanoma cells by potentially activating both TRAIL‐based, and mitochondrial‐based, apoptosis by targeting either glucose or glutamine metabolic pathways for future melanoma therapeutic trials. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B26." @default.
• W2029206266 created "2016-06-24" @default.
• W2029206266 creator A5025565506 @default.
• W2029206266 creator A5032356581 @default.
• W2029206266 creator A5065426791 @default.
• W2029206266 date "2009-12-10" @default.
• W2029206266 modified "2023-09-25" @default.
• W2029206266 title "Abstract B26: Targeting glucose and glutamine metabolism in melanoma cells influences Noxa and Mcl‐1 levels as well as susceptibility to TRAIL‐induced apoptosis" @default.
• W2029206266 doi "https://doi.org/10.1158/1535-7163.targ-09-b26" @default.
• W2029206266 hasPublicationYear "2009" @default.
• W2029206266 type Work @default.
• W2029206266 sameAs 2029206266 @default.
• W2029206266 citedByCount "0" @default.
• W2029206266 crossrefType "proceedings-article" @default.
• W2029206266 hasAuthorship W2029206266A5025565506 @default.
• W2029206266 hasAuthorship W2029206266A5032356581 @default.
• W2029206266 hasAuthorship W2029206266A5065426791 @default.
• W2029206266 hasConcept C121608353 @default.
• W2029206266 hasConcept C185592680 @default.
• W2029206266 hasConcept C190283241 @default.
• W2029206266 hasConcept C2777658100 @default.
• W2029206266 hasConcept C2779349466 @default.
• W2029206266 hasConcept C31573885 @default.
• W2029206266 hasConcept C502942594 @default.
• W2029206266 hasConcept C503630168 @default.
• W2029206266 hasConcept C515207424 @default.
• W2029206266 hasConcept C54355233 @default.
• W2029206266 hasConcept C55493867 @default.
• W2029206266 hasConcept C81885089 @default.
• W2029206266 hasConcept C86803240 @default.
• W2029206266 hasConcept C88634738 @default.
• W2029206266 hasConcept C96232424 @default.
• W2029206266 hasConceptScore W2029206266C121608353 @default.
• W2029206266 hasConceptScore W2029206266C185592680 @default.
• W2029206266 hasConceptScore W2029206266C190283241 @default.
• W2029206266 hasConceptScore W2029206266C2777658100 @default.
• W2029206266 hasConceptScore W2029206266C2779349466 @default.
• W2029206266 hasConceptScore W2029206266C31573885 @default.
• W2029206266 hasConceptScore W2029206266C502942594 @default.
• W2029206266 hasConceptScore W2029206266C503630168 @default.
• W2029206266 hasConceptScore W2029206266C515207424 @default.
• W2029206266 hasConceptScore W2029206266C54355233 @default.
• W2029206266 hasConceptScore W2029206266C55493867 @default.
• W2029206266 hasConceptScore W2029206266C81885089 @default.
• W2029206266 hasConceptScore W2029206266C86803240 @default.
• W2029206266 hasConceptScore W2029206266C88634738 @default.
• W2029206266 hasConceptScore W2029206266C96232424 @default.
• W2029206266 hasLocation W20292062661 @default.
• W2029206266 hasOpenAccess W2029206266 @default.
• W2029206266 hasPrimaryLocation W20292062661 @default.
• W2029206266 hasRelatedWork W1128538411 @default.
• W2029206266 hasRelatedWork W1141456258 @default.
• W2029206266 hasRelatedWork W1560524291 @default.
• W2029206266 hasRelatedWork W1975230462 @default.
• W2029206266 hasRelatedWork W1979430346 @default.
• W2029206266 hasRelatedWork W2017168297 @default.
• W2029206266 hasRelatedWork W2023792419 @default.
• W2029206266 hasRelatedWork W2092385448 @default.
• W2029206266 hasRelatedWork W2113212894 @default.
• W2029206266 hasRelatedWork W2127113815 @default.
• W2029206266 hasRelatedWork W2411853640 @default.
• W2029206266 hasRelatedWork W2507947308 @default.
• W2029206266 hasRelatedWork W2568790842 @default.
• W2029206266 hasRelatedWork W2741998068 @default.
• W2029206266 hasRelatedWork W2785593560 @default.
• W2029206266 hasRelatedWork W2890853886 @default.
• W2029206266 hasRelatedWork W2972267586 @default.
• W2029206266 hasRelatedWork W2990360398 @default.
• W2029206266 hasRelatedWork W565414638 @default.
• W2029206266 hasRelatedWork W2104956110 @default.
• W2029206266 isParatext "false" @default.
• W2029206266 isRetracted "false" @default.
• W2029206266 magId "2029206266" @default.
• W2029206266 workType "article" @default.